10 point ventures LLC

767 third avenue
new york, new york 10017

NYS Entity Status
ACTIVE

NYS Filing Date
JUNE 10, 2014

NYS DOS ID#
4589908

County
NEW YORK

Jurisdiction
NEW YORK

Registered Agent
RICHARD N. COHEN, ESQ.
COHEN & COLEMAN, LLP
767 THIRD AVENUE
NEW YORK, NEW YORK, 10017

NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY

Name History
2014 - 10 POINT VENTURES LLC









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • AROUND THE WEB

  • Women of Sex Tech, Unite
    By ANNA NORTH - Friday Aug 18, 2017

    New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.

    Source: NYT > Home Page
  • Dan Loeb buys a chunk of Nestle, blasts ‘staid’ culture
    By Carleton English - Monday Jun 26, 2017

    Dan Loeb just placed his biggest bet ever on a chocolate company. The activist investor’s hedge fund Third Point LLC amassed a $3.5 billion stake in Nestle, the world’s largest packaged foods company, representing roughly 1.25 percent of the Swiss-based company’s shares. Loeb is hoping to reinvigorate the brand amid changing food tastes as well...

    Source: New York Post: Business
  • Fit City: Taking Night-Life Cue, Gyms Lower the Lights
    By TATIANA BONCOMPAGNI - Tuesday Jun 13, 2017

    Cycling, boxing and running studios, as well as some full-service gyms, are using sophisticated lighting systems to heighten the exercise experience.

    Source: NYT > Home Page
  • Pride 2017: New York’s L.G.B.T.Q. Story Began Well Before Stonewall
    By LIAM STACK - Monday Jun 19, 2017

    The gay bar’s 1969 patron-police battle, hailed as a starting point, actually followed many events in the city, now mapped in a sites project.

    Source: NYT > Home Page
  • IFM Gets $300M Bristol Buyout, Plans Second Strike With New Spinout
    By Ben Fidler - Thursday Aug 3, 2017

    Bristol-Myers Squibb this afternoon is acquiring a young startup, IFM Therapeutics, in an unusual deal that will also see the big drugmaker get a chance to own rights in a new company the biotech is spinning out as well. New York-based Bristol (NYSE: BMY) will pay $300 million up front for IFM, which will give […]

    Source: Xconomy New York
10 point ventures llc new york ny